Aldeyra Therapeutics (NASDAQ:ALDX – Get Rating) had its price target lifted by research analysts at Oppenheimer to $11.00 in a note issued to investors on Thursday, Stock Target Advisor reports. Oppenheimer’s price objective would indicate a potential upside of 184.97% from the company’s current price.
Several other research analysts have also commented on ALDX. HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Aldeyra Therapeutics in a report on Wednesday, April 27th. StockNews.com initiated coverage on Aldeyra Therapeutics in a report on Thursday, March 31st. They issued a “sell” rating for the company. Berenberg Bank began coverage on shares of Aldeyra Therapeutics in a report on Tuesday, May 24th. They set a “buy” rating and a $28.00 target price for the company. Finally, Citigroup lifted their price objective on Aldeyra Therapeutics from $21.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $19.00.
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%!
When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
ALDX traded up $0.36 during trading on Thursday, reaching $3.86. 2,786,692 shares of the company’s stock were exchanged, compared to its average volume of 902,268. The firm has a fifty day moving average price of $3.43 and a two-hundred day moving average price of $4.28. The company has a current ratio of 13.60, a quick ratio of 13.60 and a debt-to-equity ratio of 0.08. Aldeyra Therapeutics has a one year low of $2.36 and a one year high of $12.78. The stock has a market capitalization of $225.04 million, a PE ratio of -3.48 and a beta of 1.64.
Aldeyra Therapeutics (NASDAQ:ALDX – Get Rating) last announced its earnings results on Thursday, May 5th. The biotechnology company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.02. During the same quarter in the previous year, the company posted ($0.25) earnings per share. Sell-side analysts expect that Aldeyra Therapeutics will post -1.37 earnings per share for the current year.
Hedge funds have recently modified their holdings of the stock. Point72 Hong Kong Ltd acquired a new stake in shares of Aldeyra Therapeutics during the 4th quarter worth approximately $31,000. ProShare Advisors LLC acquired a new stake in Aldeyra Therapeutics in the 4th quarter worth about $43,000. Kestra Advisory Services LLC boosted its holdings in Aldeyra Therapeutics by 33.4% in the 4th quarter. Kestra Advisory Services LLC now owns 16,809 shares of the biotechnology company’s stock worth $67,000 after buying an additional 4,212 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in Aldeyra Therapeutics by 98.7% in the 4th quarter. MetLife Investment Management LLC now owns 18,715 shares of the biotechnology company’s stock worth $75,000 after buying an additional 9,298 shares during the last quarter. Finally, BNP Paribas Arbitrage SA boosted its holdings in Aldeyra Therapeutics by 370.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 8,664 shares of the biotechnology company’s stock worth $76,000 after buying an additional 6,821 shares during the last quarter. Institutional investors own 62.94% of the company’s stock.
About Aldeyra Therapeutics (Get Rating)
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in Aldeyra Therapeutics right now?
Before you consider Aldeyra Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Aldeyra Therapeutics wasn’t on the list.
While Aldeyra Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com